Tsumura & Co banner

Tsumura & Co
TSE:4540

Watchlist Manager
Tsumura & Co Logo
Tsumura & Co
TSE:4540
Watchlist
Price: 3 700 JPY 0.22% Market Closed
Market Cap: ¥284B

EV/FCFF

-14
Current
27%
Cheaper
vs 3-y average of -19.2

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
-14
=
Enterprise Value
¥360.6B
/
Free Cash Flow to Firm
¥-23.7B

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
-14
=
Enterprise Value
¥360.6B
/
Free Cash Flow to Firm
¥-23.7B

Valuation Scenarios

Tsumura & Co is trading above its 5-year average

If EV/FCFF returns to its 5-Year Average (20.6), the stock would be worth ¥-5 447.49 (247% downside from current price).

Statistics
Positive Scenarios
0/3
Maximum Downside
-249%
Maximum Upside
No Upside Scenarios
Average Downside
246%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple -14 ¥3 700
0%
5-Year Average 20.6 ¥-5 447.49
-247%
Industry Average 19.9 ¥-5 257.42
-242%
Country Average 20.9 ¥-5 509.64
-249%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
JP
Tsumura & Co
TSE:4540
275.8B JPY -14 9.5
US
Eli Lilly and Co
NYSE:LLY
825.8B USD 144 40
US
Johnson & Johnson
NYSE:JNJ
548.5B USD 29.2 26.1
CH
Roche Holding AG
SIX:ROG
248.4B CHF 26.4 20.1
UK
AstraZeneca PLC
LSE:AZN
215.6B GBP 35.3 27.9
CH
Novartis AG
SIX:NOVN
218.9B CHF 19.2 19.6
US
Merck & Co Inc
NYSE:MRK
272.3B USD 24.6 14.9
IE
Endo International PLC
LSE:0Y5F
244.4B USD 1 486.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 43.8 11.5
US
Pfizer Inc
NYSE:PFE
150.6B USD 21.9 19.4
US
Bristol-Myers Squibb Co
NYSE:BMY
117.3B USD 11.7 16.6
P/E Multiple
Earnings Growth PEG
JP
Tsumura & Co
TSE:4540
Average P/E: 20.6
9.5
-2%
N/A
US
Eli Lilly and Co
NYSE:LLY
40
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.1
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
27.9
25%
1.1
CH
Novartis AG
SIX:NOVN
19.6
14%
1.4
US
Merck & Co Inc
NYSE:MRK
14.9
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.4
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.6
16%
1

Market Distribution

Lower than 100% of companies in Japan
Percentile
0th
Based on 3 767 companies
0th percentile
-14
Low
0 — 13.6
Typical Range
13.6 — 32.2
High
32.2 —
Distribution Statistics
Japan
Min 0
30th Percentile 13.6
Median 20.9
70th Percentile 32.2
Max 571 930 627.1

Tsumura & Co
Glance View

Market Cap
284B JPY
Industry
Pharmaceuticals

Tsumura & Co., a venerable name in the herbal medicine industry, traces its roots back to 1893. Emerging from Japan's rich pharmacopeia tradition, the company has carved a niche by blending age-old herbal knowledge with contemporary research and quality control. This synergy allows Tsumura to thrive in the modern marketplace, offering Kampo—a traditional Japanese herbal medicine—as their primary product line. Tsumura stands out in its meticulous approach to sourcing high-quality raw materials, employing state-of-the-art technology to ensure efficacy and safety. This rigorous quality assurance not only honors the integrity of traditional formulas but also aligns with the stringent standards of modern healthcare. In its pursuit of growth, Tsumura expertly navigates the delicate balance between tradition and innovation. The company generates revenue through the sale of its Kampo products, which are widely used in clinics and hospitals across Japan, reflecting a significant integration into the mainstream healthcare system. Additionally, Tsumura's strategic collaborations with pharmaceutical companies expand its reach into international markets. Through educational initiatives, they further advocate for the understanding and acceptance of herbal medicine globally. By continually investing in research and development, Tsumura aims to bolster their product offerings, ensuring that the ancient wisdom of Kampo remains relevant in today's fast-paced, health-conscious world.

Intrinsic Value
3 472.39 JPY
Overvaluation 6%
Intrinsic Value
Price ¥3 700
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett